Latest Content

Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.

Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.

Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.

Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.